In comparison, the average weight loss in the phase 3 clinical trials was 14.9% for once-weekly semaglutide 2.4 mg, 15.0% for tirzepatide 5 mg, and 20.9% for tirzepatide 15 mg.

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

The EMBRAZE trial was designed to assess the ability to preserve lean body mass associated with tirzepatide-induced weight loss in patients with obesity (BMI of ≥30.0 kg/m 2) or overweight (BMI ...

Apitegromab therapy (10 mg/kg) with tirzepatide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tirzepatide alone, leading to higher quality weight loss.

By Hugo Francisco de Souza A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ...

The study included 7881 patients: 6109 and 1772 received semaglutide and tirzepatide, respectively; 80.8% had low maintenance dosages.

Reviewed by Susha Cheriyedath, M.Sc. Jun 25 2025 A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment.

DIY tirzepatide, internet detective work and insurance appeals: The lengths 3 people are going to for weight loss drugs "Not being on it is not an option." Natalie Rahhal, Reporter ...

THURSDAY, June 12, 2025 (HealthDay News) -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower ...

Research Summary Tirzepatide vs. Semaglutide for the Treatment of Obesity July 2, 2025 DOI: 10.1056/NEJMdo008041 Save ...